Purpose: To demonstrate the reduction in vascular bed volume (VBV) of uterine fibroids after administration of gonadotropin-releasing hormone analogue (GnRHa) using magnetic resonance (MR) imaging including dynamic double-echo R2* imaging (DDE-R2*I) and to assess the value of DDE-R2*I as a predictor of such reduction. Methods: Twenty-one women with uterine intramural fibroids underwent MR imaging including DDE-R2*I before GnRHa treatment. DDE-R2*I was acquired using a single-section, double-echo, fast spoiled gradient recalled acquisition in the steady state (SPGR) sequence. We calculated the area under the curve (AUC) of the signal intensity on R2*I within a 3×3-cm2 region of interest that served to represent the VBV. We repeated MR imaging after 2 administrations of GnRHa and repeated image analyses. We statistically analyzed correlations between (A) pre-treatment AUC (AUC(pre)) and AUC reduction and (B) AUC(pre) and volume reduction. Results: The interval between the 2 MR studies ranged from 56 to 119 days (mean: 80.4 days). The average volume of the fibroids before GnRHa treatment was 647.8 mL compared with 463.4 mL after the therapy (decreased by an average of 28.5z; P<0.0001). Meanwhile, measured AUC was reduced by 55.3z(483.4 vs. 206.5; P<0.0001). AUC(pre) correlated with volume reduction (r=0.68), but not AUC reduction. Conclusions: We confirmed reduction in the VBV of fibroids using DDE-R2*I. The measurement of AUC(pre) on DDE-R2*I aids prediction of fibroid volume reduction but correlates poorly with the percentage of AUC reduction.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging